Stockreport

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Eledon Pharmaceuticals, Inc.  (ELDN) 
PDF Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities [Read more]